Squarepoint
ADCT icon

Squarepoint’s ADC Therapeutics ADCT Stock Holding History

Squarepoint’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-156,126
Closed -$585K – 4338
2026
Q1 		$585K Sell
156,126
-17,741
-10% -$69.9K ﹤0.01% 3207
2025
Q4 		$614K Sell
173,867
-1,076
-0.6% -$4.37K ﹤0.01% 3046
2025
Q3 		$700K Buy
174,943
+148,060
+551% +$467K ﹤0.01% 2951
2025
Q2 		$72K Sell
26,883
-64,990
-71% -$137K ﹤0.01% 4249
2025
Q1 		$130K Sell
91,873
-15,358
-14% -$26.1K ﹤0.01% 4146
2024
Q4 		$213K Buy
107,231
+31,839
+42% +$83.3K ﹤0.01% 4422
2024
Q3 		$237K Buy
+75,392
New +$238K ﹤0.01% 3594
2023
Q3 		– Sell
-44,641
Closed -$96K – 3729
2023
Q2 		$96K Sell
44,641
-59,906
-57% -$135K ﹤0.01% 3370
2023
Q1 		$204K Buy
+104,547
New +$386K ﹤0.01% 2796
2022
Q3 		– Sell
-11,014
Closed -$88K – 2936
2022
Q2 		$88K Buy
+11,014
New +$104K ﹤0.01% 2638

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Squarepoint's ADCT Position: Q2 2026 in Review

Squarepoint sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 156,126 shares — an estimated $585K sold.

Squarepoint first reported a position in ADCT in Q2 2022 and held it in 10 quarters. The position peaked at $700K in Q3 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Squarepoint reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 156,126 ADC Therapeutics shares in Q2 2026, an estimated $585K.
  • Squarepoint first reported a position in ADC Therapeutics in Q2 2022 and held it in 10 quarters.
  • Squarepoint's ADC Therapeutics position peaked at $700K in Q3 2025.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.